伏诺拉生高剂量二联、伏诺拉生三联与雷贝拉唑反向混合疗法用于幽门螺杆菌感染一线治疗:多中心随机试验
这项在台湾6个中心开展的多中心随机开放标签试验,连续纳入906例成人幽门螺杆菌感染者,1:1:1随机接受14天伏诺拉生高剂量二联、伏诺拉生三联或雷贝拉唑反向混合疗法。意向性分析根除率分别为83.8%、90.1%和89.1%,伏诺拉生高剂量二联劣于后两者;三组不良事件总比例无显著差异。
要点
- 伏诺拉生三联(90.1%)与雷贝拉唑反向混合疗法(89.1%)根除率优于伏诺拉生高剂量二联(83.8%)。
- 伏诺拉生高剂量二联分别劣于伏诺拉生三联和雷贝拉唑反向混合疗法。
- 三组不良事件总比例无显著差异(10.3%、15.2%、15.6%)。
核心结论
- 作者认为,伏诺拉生三联疗法和雷贝拉唑反向混合疗法优于伏诺拉生二联疗法用于幽门螺杆菌感染的一线治疗。
研究设计与样本
- 多中心、随机、开放标签试验,连续纳入台湾6个中心的成人幽门螺杆菌感染患者。
- 受试者按1:1:1随机分配至14天伏诺拉生高剂量二联、伏诺拉生三联或雷贝拉唑反向混合疗法。
- 根除状态通过13C-尿素呼气试验判定,主要结局为意向性治疗人群的幽门螺杆菌根除率。
主要发现
- 2021年12月至2024年4月共纳入906例患者。
- 意向性治疗分析根除率:伏诺拉生高剂量二联83.8%(253/302),伏诺拉生三联90.1%(272/302),雷贝拉唑反向混合疗法89.1%(271/302)。
- 伏诺拉生高剂量二联劣于伏诺拉生三联(95%CI -11.5%至-1.1%;P=0.022)和雷贝拉唑反向混合疗法(95%CI -10.7%至0.1%;P=0.031)。
- 三组不良事件总比例无显著差异:伏诺拉生高剂量二联10.3%、伏诺拉生三联15.2%、雷贝拉唑反向混合疗法15.6%。
- 体重≥60 kg、克拉霉素耐药和服药依从性差是三种相应疗法根除失败的独立危险因素,OR分别为3.2(1.3-7.5)、4.8(1.2-18.9)和14.8(2.8-78.8)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of this study was to compare the efficacy of 14-day vonoprazan high-dose dual, vonoprazan triple, and rabeprazole reverse hybrid therapies for the first-line treatment of Helicobacter pylori infection. METHODS: In the multicenter, randomized, open-label trial, we consecutively recruited adult H. pylori -infected patients from 6 centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day vonoprazan high-dose dual, vonoprazan triple, or rabeprazole reverse hybrid therapy. Eradication status was determined by 13 C-urea breath test. The primary outcome was the eradication rate of H. pylori assessed in the intention-to-treat population. RESULTS: Between December 2021 and April 2024, 906 patients were recruited. The eradication rates were 83.8% (253/302) for vonoprazan high-dose dual therapy, 90.1% (272/302) for vonoprazan triple therapy, and 89.1% (271/302) for rabeprazole reverse hybrid therapy in intention-to-treat analysis. Vonoprazan high-dose dual therapy was inferior to both vonoprazan triple (95% confidence interval -11.5% to -1.1%; P = 0.022) and rabeprazole reverse hybrid therapies (95% confidence interval -10.7% to 0.1%; P = 0.031). There were no significant differences in the overall proportions of patients experiencing adverse events among vonoprazan high-dose dual, vonoprazan triple, and rabeprazole reverse hybrid groups (10.3%, 15.2%, and 15.6%, respectively). Body weight ≥60 kg, clarithromycin resistance, and poor drug adherence were independent risk factors predicting eradication failure for the 3 corresponding therapies, with odds ratios of 3.2 (1.3-7.5), 4.8 (1.2-18.9), and 14.8 (2.8-78.8), respectively. DISCUSSION: Vonoprazan triple therapy and rabeprazole reverse hybrid therapy are preferable to vonoprazan dual therapy for the first-line treatment of H. pylori infection.
引用
- Hsu PI, Chen CL, Shih CA, et al. Vonoprazan High-Dose Dual, Vonoprazan Triple, and Rabeprazole Reverse Hybrid Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter Randomized Trial. Am J Gastroenterol. 2025. PMID: 40560185. doi:10.14309/ajg.0000000000003607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。